Reviewer's report

Title: Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: Study protocol for a prospective randomized study NCT01159639

Version: 3 Date: 18 June 2012

Reviewer: Roxana Mehran

Reviewer's report:

Major Compulsory Revisions:
- The authors need to discuss in detail their power calculations for this trial; how many patients do they anticipate recruiting? How will they deal with cross-over and loss to follow-up? Will the analysis be intention to treat or per-protocol?
- Why is this trial not placebo controlled?
- The authors need to describe in more detail clinical event adjudication
- How will the bleeding events be adjudicated? Will the authors use standard definitions (TIMI, GUSTO etc.)? We would recommend the BARC bleeding scale (Bleeding Academic Research Consortium)

Minor Essential Revisions:
- The introduction is too long; please divide into 3 paragraphs, and please include the clinical guidelines on antiplatelet therapy after CABG
- The manuscript needs some editing
- Please define ASPI

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

AstraZeneca, Consultant
Ortho McNeill-Janssen, Advisory Board
Regado, Advisory Board
BMS/Sanofi, Research Grant Support (institutional)
The Medicines Co., Research Grant Support (spouse)